CeriBell (NASDAQ:CBLL) Trading 9.1% Higher – Should You Buy?

CeriBell (NASDAQ:CBLL)’s share price rose 9.1% during trading on Tuesday . The stock traded as high as $22.91 and last traded at $22.95. Approximately 113,825 shares traded hands during mid-day trading, a decline of 46% from the average daily volume of 210,938 shares. The stock had previously closed at $21.04.

Analyst Ratings Changes

Several research firms have recently weighed in on CBLL. Canaccord Genuity Group assumed coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 target price for the company. Canaccord Genuity Group raised their price target on CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 9th. JPMorgan Chase & Co. began coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective for the company. William Blair started coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “outperform” rating for the company. Finally, TD Cowen increased their price objective on shares of CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell currently has an average rating of “Buy” and a consensus price target of $32.60.

CeriBell Trading Up 9.0 %

The firm has a 50 day moving average of $26.14.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The firm had revenue of $17.20 million during the quarter, compared to analyst estimates of $17.06 million. As a group, equities analysts expect that CeriBell will post -2.46 earnings per share for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.